NCT06270238 Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Upper Limb Function in Subacute Stroke Patients
| NCT ID | NCT06270238 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-02-13 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2024-02-13 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each hemiplegic stroke patient in subacute phase, compared to conventional low-frequency rTMS therapy on contralateral M1. Investigators hypothesized that the functional reserve of each hemiplegic stroke patient will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to stroke patients regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.
Eligibility Criteria
Inclusion Criteria: 1. hemiplegic stroke patients in the subacute phase (7 days to 3 months from the onset) who are currently hospitalized, 2. FMA score of the upper extremity ≤42, 3. adequate language and cognitive function to perform at least a 1-step obey-command, 4. pre-stroke functional level of modified Rankin Scale (mRS) ≤1, 5. aged ≥19 years old, 6. patients willing to sign the informed consent. Exclusion Criteria: 1. those with contraindications to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy, 2. those with progressive of hemodynamically unstable medical conditions, 3. those with coexisting neurological conditions, such as spinal cord injury or Parkinson's disease, 4. those with major psychiatric disorders, such as major depression, schizophrenia, or dementia, 5. those having contraindications to conduct an MRI study, 6. those who are pregnant or lactating , 7. patients who have refused to participate in this study.
Contact & Investigator
Won Hyuk Chang, PhD
PRINCIPAL INVESTIGATOR
Samsung Medical Center
Frequently Asked Questions
Who can join the NCT06270238 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06270238 currently recruiting?
Yes, NCT06270238 is actively recruiting participants. Contact the research team at wh.chang@samsung.com for enrollment information.
Where is the NCT06270238 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06270238 clinical trial?
NCT06270238 is sponsored by Samsung Medical Center. The principal investigator is Won Hyuk Chang, PhD at Samsung Medical Center. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.